← Back to Screener
ArriVent BioPharma, Inc. Common Stock (AVBP)
Price$31.39
Favorite Metrics
Price vs S&P 500 (26W)33.34%
Price vs S&P 500 (4W)25.11%
Market Capitalization$1.31B
All Metrics
Book Value / Share (Quarterly)$7.24
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.78
Price vs S&P 500 (YTD)43.18%
EPS (TTM)$-4.46
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$-4.46
EPS (Annual)$-4.32
ROI (Annual)-54.13%
Cash / Share (Quarterly)$7.37
ROA (Last FY)-49.92%
EBITD / Share (TTM)$-4.62
ROE (5Y Avg)-55.51%
Cash Flow / Share (Annual)$-3.78
P/B Ratio4.26x
P/B Ratio (Quarterly)2.70x
Net Income / Employee (Annual)$-2
ROA (TTM)-58.11%
EPS Incl Extra (Annual)$-4.32
Current Ratio (Annual)12.83x
Quick Ratio (Quarterly)12.83x
3-Month Avg Trading Volume0.49M
52-Week Price Return65.59%
Revenue / Employee (TTM)$0
52-Week High$30.72
EPS Excl Extra (Annual)$-4.32
26-Week Price Return42.09%
Quick Ratio (Annual)12.83x
13-Week Price Return31.91%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.83x
Enterprise Value$1,264.596
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.37
3-Month Return Std Dev61.65%
Net Income / Employee (TTM)$-2
ROE (Last FY)-54.13%
EPS Basic Excl Extra (Annual)$-4.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.46
ROI (TTM)-62.48%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)30.49%
Year-to-Date Return47.32%
5-Day Price Return10.64%
EPS Normalized (Annual)$-4.32
ROA (5Y Avg)-52.36%
Month-to-Date Return28.48%
EBITD / Share (Annual)$-4.62
ROI (5Y Avg)-55.51%
EPS Basic Excl Extra (TTM)$-4.46
P/B Ratio (Annual)2.70x
Book Value / Share (Annual)$7.24
Price vs S&P 500 (13W)29.04%
Beta0.91x
Revenue / Share (TTM)$0.00
ROE (TTM)-62.48%
52-Week Low$16.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.32
4.32
4.32
4.32
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AVBPArriVent BioPharma, Inc. Common Stock | — | — | — | — | $31.39 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing differentiated cancer therapeutics with an initial focus on solid tumors. The company's lead candidate, furmonertinib, is in clinical development, supported by a pipeline that includes next-generation antibody-drug conjugates designed to address unmet oncology needs.